Effect of Altering Dietary Omega-6/omega-3 Fatty Acid Ratios on Prostate Cancer Membrane Composition, Cyclooxygenase-2, and Prostaglandin E2
Overview
Authors
Affiliations
Purpose: To determine whether altering the dietary content of omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids affects the growth of androgen-sensitive prostate cancer xenografts, tumor membrane fatty acid composition, and tumor cyclooxygenase-2 and prostaglandin E(2) (PGE(2)) levels.
Experimental Design: Individually caged male severe combined immunodeficiency mice were fed isocaloric 20% kcal fat diets with the fat derived either primarily from n-6 fatty acids (n-6 group) or with the fat consisting of n-6 and n-3 fatty acids in a ratio of 1:1 (n-3 group), and injected s.c. with Los Angeles Prostate Cancer 4 (LAPC-4) cells. Tumor volumes and mouse weights were measured weekly, caloric intake was measured 3 days per week, and tumors and serum were harvested at 8 weeks postinjection.
Results: Tumor growth rates, final tumor volumes, and serum prostate-specific antigen levels were reduced in the n-3 group relative to the n-6 group. The n-3 group tumors had decreased proliferation (Ki67 staining) and increased apoptosis (terminal nucleotidyl transferase-mediated nick end labeling staining). In vitro proliferation of LAPC-4 cells in medium containing n-3 group serum was reduced by 22% relative to LAPC-4 cells cultured in medium containing serum from the n-6 group. The n-6/n-3 fatty acid ratios in serum and tumor membranes were lower in the n-3 group relative to the n-6 group. In addition, n-3 group tumors had decreased cyclooxygenase-2 protein and mRNA levels, an 83% reduction in PGE(2) levels, and decreased vascular endothelial growth factor expression.
Conclusion: These results provide a sound basis for clinical trials evaluating the effect of dietary n-3 fatty acids from fish oil on tumor PGE(2) and membrane fatty acid composition, and serum and tumor biomarkers of progression in men with prostate cancer.
The effects of glycemic index on prostate cancer progression in a xenograft mouse model.
Galvan G, Macias E, Sanders S, Ramirez-Torres A, Stock S, You S Prostate Cancer Prostatic Dis. 2023; 27(2):348-354.
PMID: 38082056 PMC: 11096094. DOI: 10.1038/s41391-023-00769-w.
THEM6 is a prognostic biomarker for breast cancer and is associated with immune infiltration.
Lu X, Chen W, Tian G, Ge F Sci Rep. 2023; 13(1):21974.
PMID: 38081884 PMC: 10713618. DOI: 10.1038/s41598-023-49379-5.
Minelli G, DAmbra K, Macchioni P, Fiego D Foods. 2023; 12(22).
PMID: 38002164 PMC: 10670070. DOI: 10.3390/foods12224106.
Liang P, Henning S, Grogan T, Elashoff D, Said J, Cohen P Prostate Cancer Prostatic Dis. 2023; 27(4):700-708.
PMID: 37872251 PMC: 11035487. DOI: 10.1038/s41391-023-00745-4.
Sadeghi H, Lynch C, Field W, Snetselaar L, Jones M, Sinha R Cancer Epidemiol. 2023; 85:102410.
PMID: 37413804 PMC: 10528409. DOI: 10.1016/j.canep.2023.102410.